These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 27447750)

  • 1. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
    Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
    Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
    Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.
    Hatem L; McIntire PJ; He B; Gogineni S; Ho M; Mathew S; Margolskee EM; Siddiqui MT; Rao RA
    Diagn Cytopathol; 2019 Mar; 47(3):160-165. PubMed ID: 30520251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
    Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
    McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
    Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
    Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
    Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
    Cozzi I; Oprescu FA; Rullo E; Ascoli V
    Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
    Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
    Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
    Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumours.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Nabeshima K
    Histopathology; 2017 Dec; 71(6):1011-1014. PubMed ID: 28746778
    [No Abstract]   [Full Text] [Related]  

  • 13. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
    Hakim SA; Abou Gabal HH
    Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology.
    Louw A; Lee YCG; Acott N; Creaney J; van Vliet C; Chai SM
    Cytopathology; 2022 Jan; 33(1):84-92. PubMed ID: 34033161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.
    Mlika M; Zorgati M; BenKhelil M; Mezni FE
    J Immunoassay Immunochem; 2019; 40(3):269-282. PubMed ID: 30810450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
    Nasu M; Emi M; Pastorino S; Tanji M; Powers A; Luk H; Baumann F; Zhang YA; Gazdar A; Kanodia S; Tiirikainen M; Flores E; Gaudino G; Becich MJ; Pass HI; Yang H; Carbone M
    J Thorac Oncol; 2015 Apr; 10(4):565-76. PubMed ID: 25658628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations.
    Chapel DB; Husain AN; Krausz T
    Mod Pathol; 2019 Mar; 32(3):376-386. PubMed ID: 30315275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
    Jaouen A; Thivolet-Bejui F; Chalabreysse L; Piaton E; Traverse-Glehen A; Isaac S; Decaussin-Petrucci M; Depaepe L; Fontaine J; Remy I; Maury JM; Brevet M
    Ann Pathol; 2016 Apr; 36(2):111-9. PubMed ID: 26995100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma.
    Devins KM; Zukerberg L; Watkins JC; Hung YP; Oliva E
    Int J Gynecol Pathol; 2023 Mar; 42(2):159-166. PubMed ID: 35512220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.